Although we have shown non-inferiority for trastuzumab in the population we tested, discussion and intense debate about our results is ongoing, including whether or not these are applicable in 2019 compared with 2007 when the study was designed, because of the changes in standard treatments for patients with HER2-positive breast cancer that have occurred. This evidence concerns the gene ERBB2 and breast cancer.